Inogen (NASDAQ:INGN – Get Rating) will be posting its quarterly earnings results after the market closes on Thursday, May 5th. Analysts expect Inogen to post earnings of ($0.47) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
Inogen (NASDAQ:INGN – Get Rating) last released its quarterly earnings results on Thursday, February 24th. The medical technology company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.27). Inogen had a negative return on equity of 1.70% and a negative net margin of 1.77%. The company had revenue of $76.40 million for the quarter, compared to analysts’ expectations of $76.60 million. During the same period in the previous year, the business posted ($0.23) EPS. The business’s quarterly revenue was up 3.3% on a year-over-year basis. On average, analysts expect Inogen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
INGN stock opened at $26.16 on Thursday. Inogen has a 52-week low of $25.92 and a 52-week high of $82.35. The stock’s fifty day simple moving average is $31.24 and its 200-day simple moving average is $32.85. The stock has a market capitalization of $597.39 million, a price-to-earnings ratio of -90.20 and a beta of 0.91.
A number of institutional investors have recently modified their holdings of INGN. Norges Bank acquired a new position in Inogen in the fourth quarter valued at $9,778,000. BlackRock Inc. raised its position in Inogen by 7.3% in the fourth quarter. BlackRock Inc. now owns 3,373,036 shares of the medical technology company’s stock valued at $114,685,000 after purchasing an additional 230,762 shares during the period. State Street Corp raised its position in Inogen by 7.1% in the fourth quarter. State Street Corp now owns 929,903 shares of the medical technology company’s stock valued at $31,617,000 after purchasing an additional 61,448 shares during the period. Geode Capital Management LLC raised its position in Inogen by 20.8% in the fourth quarter. Geode Capital Management LLC now owns 348,619 shares of the medical technology company’s stock valued at $11,853,000 after purchasing an additional 60,010 shares during the period. Finally, Citadel Advisors LLC raised its position in Inogen by 64.0% in the fourth quarter. Citadel Advisors LLC now owns 106,330 shares of the medical technology company’s stock valued at $3,615,000 after purchasing an additional 41,495 shares during the period. Hedge funds and other institutional investors own 93.22% of the company’s stock.
Several equities research analysts have recently issued reports on INGN shares. StockNews.com started coverage on Inogen in a report on Thursday, March 31st. They set a “hold” rating on the stock. TheStreet cut Inogen from a “c-” rating to a “d” rating in a report on Friday, March 11th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Inogen presently has an average rating of “Hold” and a consensus target price of $49.80.
About Inogen (Get Rating)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
- Get a free copy of the StockNews.com research report on Inogen (INGN)
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.